Literature DB >> 22926712

EANM 2012 guidelines for radionuclide imaging of phaeochromocytoma and paraganglioma.

David Taïeb1, Henri J Timmers, Elif Hindié, Benjamin A Guillet, Hartmut P Neumann, Martin K Walz, Giuseppe Opocher, Wouter W de Herder, Carsten C Boedeker, Ronald R de Krijger, Arturo Chiti, Adil Al-Nahhas, Karel Pacak, Domenico Rubello.   

Abstract

PURPOSE: Radionuclide imaging of phaeochromocytomas (PCCs) and paragangliomas (PGLs) involves various functional imaging techniques and approaches for accurate diagnosis, staging and tumour characterization. The purpose of the present guidelines is to assist nuclear medicine practitioners in performing, interpreting and reporting the results of the currently available SPECT and PET imaging approaches. These guidelines are intended to present information specifically adapted to European practice.
METHODS: Guidelines from related fields, issued by the European Association of Nuclear Medicine and the Society of Nuclear Medicine, were taken into consideration and are partially integrated within this text. The same was applied to the relevant literature, and the final result was discussed with leading experts involved in the management of patients with PCC/PGL. The information provided should be viewed in the context of local conditions, laws and regulations.
CONCLUSION: Although several radionuclide imaging modalities are considered herein, considerable focus is given to PET imaging which offers high sensitivity targeted molecular imaging approaches.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22926712      PMCID: PMC4714772          DOI: 10.1007/s00259-012-2215-8

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN: 1619-7070            Impact factor:   9.236


  104 in total

Review 1.  Modern PET imaging for paragangliomas: relation to genetic mutations.

Authors:  D Taïeb; D Rubello; A Al-Nahhas; M Calzada; M C Marzola; E Hindié
Journal:  Eur J Surg Oncol       Date:  2011-06-01       Impact factor: 4.424

2.  False-negative ¹²³I-MIBG SPECT is most commonly found in SDHB-related pheochromocytoma or paraganglioma with high frequency to develop metastatic disease.

Authors:  Jay S Fonte; Jeremyjones F Robles; Clara C Chen; James Reynolds; Millie Whatley; Alexander Ling; Leilani B Mercado-Asis; Karen T Adams; Victoria Martucci; Tito Fojo; Karel Pacak
Journal:  Endocr Relat Cancer       Date:  2012-02-13       Impact factor: 5.678

3.  Functional imaging of SDHx-related head and neck paragangliomas: comparison of 18F-fluorodihydroxyphenylalanine, 18F-fluorodopamine, 18F-fluoro-2-deoxy-D-glucose PET, 123I-metaiodobenzylguanidine scintigraphy, and 111In-pentetreotide scintigraphy.

Authors:  Kathryn S King; Clara C Chen; Dimitrios K Alexopoulos; Millie A Whatley; James C Reynolds; Nicholas Patronas; Alexander Ling; Karen T Adams; Paraskevi Xekouki; Howard Lando; Constantine A Stratakis; Karel Pacak
Journal:  J Clin Endocrinol Metab       Date:  2011-07-13       Impact factor: 5.958

4.  [(123)I]metaiodobenzylguanidine and [(111)In]octreotide uptake in begnign and malignant pheochromocytomas.

Authors:  E van der Harst; W W de Herder ; H A Bruining; H J Bonjer; R R de Krijger ; S W Lamberts; A H van de Meiracker ; F Boomsma; T Stijnen; E P Krenning; F T Bosman; D J Kwekkeboom
Journal:  J Clin Endocrinol Metab       Date:  2001-02       Impact factor: 5.958

5.  111In-pentetreotide scintigraphy: procedure guidelines for tumour imaging.

Authors:  Emilio Bombardieri; Valentina Ambrosini; Cumali Aktolun; Richard P Baum; Angelica Bishof-Delaloye; Silvana Del Vecchio; Lorenzo Maffioli; Luc Mortelmans; Wim Oyen; Giovanna Pepe; Arturo Chiti
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-07       Impact factor: 9.236

6.  The role of 6-[18F]fluorodopamine positron emission tomography in the localization of adrenal pheochromocytoma associated with von Hippel-Lindau syndrome.

Authors:  Priya Kaji; Jorge A Carrasquillo; W Marston Linehan; Clara C Chen; Graeme Eisenhofer; Peter A Pinto; Edwin W Lai; Karel Pacak
Journal:  Eur J Endocrinol       Date:  2007-04       Impact factor: 6.664

7.  Dopamine-producing paraganglioma not visualized by iodine-123-MIBG scintigraphy.

Authors:  T van Gelder; G T Verhoeven; P de Jong; H Y Oei; E P Krenning; V D Vuzevski; A H van den Meiracker
Journal:  J Nucl Med       Date:  1995-04       Impact factor: 10.057

8.  Modification by nifedipine of 131I-meta-iodobenzylguanidine kinetics in malignant phaeochromocytoma.

Authors:  G M Blake; V J Lewington; J S Fleming; M A Zivanovic; D M Ackery
Journal:  Eur J Nucl Med       Date:  1988

9.  Octreotide scintigraphy in the head and neck.

Authors:  A Bustillo; F Telischi; D Weed; F Civantos; S Angeli; A Serafini; M Whiteman
Journal:  Laryngoscope       Date:  2004-03       Impact factor: 3.325

10.  Comparison of radiolabeled octreotide and meta-iodobenzylguanidine (MIBG) scintigraphy in malignant pheochromocytoma.

Authors:  F Tenenbaum; J Lumbroso; M Schlumberger; A Mure; P F Plouin; B Caillou; C Parmentier
Journal:  J Nucl Med       Date:  1995-01       Impact factor: 10.057

View more
  54 in total

1.  Superiority of [68Ga]-DOTATATE PET/CT to Other Functional Imaging Modalities in the Localization of SDHB-Associated Metastatic Pheochromocytoma and Paraganglioma.

Authors:  Ingo Janssen; Elise M Blanchet; Karen Adams; Clara C Chen; Corina M Millo; Peter Herscovitch; David Taieb; Electron Kebebew; Hendrik Lehnert; Antonio T Fojo; Karel Pacak
Journal:  Clin Cancer Res       Date:  2015-04-14       Impact factor: 12.531

2.  Could 68Ga-somatostatin analogues replace other PET tracers in evaluating extra-adrenal paragangliomas?

Authors:  Giorgio Treglia; Luca Giovanella
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-12       Impact factor: 9.236

Review 3.  Molecular Imaging and Therapy for Neuroendocrine Tumors.

Authors:  Hemant Desai; Salvador Borges-Neto; Terence Z Wong
Journal:  Curr Treat Options Oncol       Date:  2019-08-29

Review 4.  Current approaches and recent developments in the management of head and neck paragangliomas.

Authors:  David Taïeb; Alexandre Kaliski; Carsten C Boedeker; Victoria Martucci; Tito Fojo; John R Adler; Karel Pacak
Journal:  Endocr Rev       Date:  2014-07-17       Impact factor: 19.871

Review 5.  Pheochromocytoma and paraganglioma: diagnosis, genetics, management, and treatment.

Authors:  Victoria L Martucci; Karel Pacak
Journal:  Curr Probl Cancer       Date:  2014-01-15       Impact factor: 3.187

6.  Succinate dehydrogenase gene mutations in cardiac paragangliomas.

Authors:  Victoria L Martucci; Abbas Emaminia; Jaydira del Rivero; Ronald M Lechan; Bindiya T Magoon; Analyza Galia; Tito Fojo; Steve Leung; Roberto Lorusso; Camilo Jimenez; Barry L Shulkin; Jennifer L Audibert; Karen T Adams; Douglas R Rosing; Anand Vaidya; Robert G Dluhy; Keith A Horvath; Karel Pacak
Journal:  Am J Cardiol       Date:  2015-03-24       Impact factor: 2.778

Review 7.  MEN2-related pheochromocytoma: current state of knowledge, specific characteristics in MEN2B, and perspectives.

Authors:  Vincent Amodru; David Taieb; Carole Guerin; Pauline Romanet; Nunzia Paladino; Thierry Brue; Thomas Cuny; Anne Barlier; Frederic Sebag; Frederic Castinetti
Journal:  Endocrine       Date:  2020-05-10       Impact factor: 3.633

8.  The adrenal medulla and extra-adrenal paraganglia: then and now.

Authors:  Arthur S Tischler; Karel Pacak; Graeme Eisenhofer
Journal:  Endocr Pathol       Date:  2014-03       Impact factor: 3.943

9.  High incidence of extraadrenal paraganglioma in families with SDHx syndromes detected by functional imaging with [18F]fluorodihydroxyphenylalanine PET.

Authors:  Matthias Miederer; Christian Fottner; Heidi Rossmann; Andreas Helisch; Konstantinos Papaspyrou; Oliver Bartsch; Wolf J Mann; Thomas J Musholt; Matthias M Weber; Karl J Lackner; Mathias Schreckenberger
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-02-02       Impact factor: 9.236

10.  18F-FDG PET/CT as a predictor of hereditary head and neck paragangliomas.

Authors:  Karel Pacak; David Taïeb; Elise M Blanchet; Sophie Gabriel; Victoria Martucci; Nicolas Fakhry; Clara C Chen; Arnaud Deveze; Corina Millo; Anne Barlier; Morgane Pertuit; Anderson Loundou
Journal:  Eur J Clin Invest       Date:  2014       Impact factor: 4.686

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.